Performance of prototypes for the ALICE electromagnetic calorimeter

The performance of prototypes for the ALICE electromagnetic sampling calorimeter has been studied in test beam measurements at FNAL and CERN. A $4\times4$ array of final design modules showed an energy resolution of about 11% /$\sqrt{E(\mathrm{GeV})}$ $\oplus$ 1.7 % with a uniformity of the response to electrons of 1% and a good linearity in the energy range from 10 to 100 GeV. The electromagnetic shower position resolution was found to be described by 1.5 mm $\oplus$ 5.3 mm /$\sqrt{E \mathrm{(GeV)}}$. For an electron identification efficiency of 90% a hadron rejection factor of $>600$ was obtained.Comment: 10 pages, 10 figure

ALICE EMCal Physics Performance Report

The ALICE detector at the LHC (A Large Ion Collider Experiment) will carry out comprehensive measurements of high energy nucleus-nucleus collisions, in order to study QCD matter under extreme conditions and the phase transtion between conï¬ned matter and the Quark-Gluon Plasma (QGP). This report presents our current state of understanding of the Physics Performance of the large acceptance Electromagnetic Calorimeter (EMCal) in the ALICE central detector. The EMCal enhances ALICEâs capabilities for jet measurements. The EMCal enables triggering and full reconstruction of high energy jets in ALICE, and augments existing ALICE capabilities to measure high momentum photons and electrons. Combined with ALICEâs excellent capabilities to track and identify particles from very low pT to high pT , the EMCal enables a comprehensive study of jet interactions in the medium produced in heavy ion collisions at the LHC.The ALICE detector at the LHC (A Large Ion Collider Experiment) will carry out comprehensive measurements of high energy nucleus-nucleus collisions, in order to study QCD matter under extreme conditions and the phase transtion between con ned matter and the Quark-Gluon Plasma (QGP). This report presents our current state of understanding of the Physics Performance of the large acceptance Electromagnetic Calorimeter (EMCal) in the ALICE central detector. The EMCal enhances ALICE s capabilities for jet measurements. The EMCal enables triggering and full reconstruction of high energy jets in ALICE, and augments existing ALICE capabilities to measure high momentum photons and electrons. Combined with ALICE s excellent capabilities to track and identify particles from very low pT to high pT , the EMCal enables a comprehensive study of jet interactions in the medium produced in heavy ion collisions at the LHC

Cardiovascular and renal outcomes with empagliflozin in heart failure

BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001). The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml per minute per 1.73 m2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONS Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes